[Efficacy of treating patients with disseminated forms of destructive pulmonary tuberculosis using chemical preparations and T-activin]. 1989

V I Chukanov, and V Ia Gergert, and I S Khomenko

The use of T-activin in combination with chemical drugs allowed to markedly increase efficacy of the treatment. As a result of the treatment significant improvement was found in 17 (41.5 per cent) out of 41 patients with marked disorders in cellular immunity and severe tuberculosis. At the same time in the patients treated with the chemotherapeutics alone the improvement was stated only in 18.5 per cent of the patients. T-Activin improved the indices of cellular immunity and eliminated imbalance in regulatory subpopulations of T-helper and T-suppressor cells.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013949 Thymus Extracts Extracts of the THYMUS GLAND that contain specific factors, peptides, and proteins with specific biological activities. Thymus Extract,Extract, Thymus,Extracts, Thymus
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1986, Problemy tuberkuleza,
V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1998, Likars'ka sprava,
V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1988, Problemy tuberkuleza,
V I Chukanov, and V Ia Gergert, and I S Khomenko
July 1996, Voenno-meditsinskii zhurnal,
V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1972, Problemy tuberkuleza,
V I Chukanov, and V Ia Gergert, and I S Khomenko
May 1982, Problemy tuberkuleza,
V I Chukanov, and V Ia Gergert, and I S Khomenko
September 1987, Antibiotiki i meditsinskaia biotekhnologiia = Antibiotics and medical biotechnology,
V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1976, Problemy tuberkuleza,
V I Chukanov, and V Ia Gergert, and I S Khomenko
January 1972, Problemy tuberkuleza,
Copied contents to your clipboard!